Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | CFTR | P13569 | 6/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29192842 | 0.87 | CFTR (0.46) | EPHX2CFTRNOTUMSOS1HTT | |
| SCHEMBL21200423 | 0.85 | TAS2R14 (0.39) | EPHX2SMN1; SMN2MAPTTSHRMEN1 | |
| SCHEMBL29866935 | 0.82 | EPHX2 (0.44) | EPHX2CFTRNOTUMSMN1; SMN2SOS1 | |
| SCHEMBL21200775 | 0.82 | EPHX2 (0.44) | EPHX2CFTRNOTUMSMN1; SMN2SOS1 | |
| SCHEMBL21200022 | 0.80 | EPHX2 (0.39) | EPHX2CFTRNOTUMSOS1 | |
| SCHEMBL29192886 | 0.80 | CFTR (0.38) | EPHX2CFTRNOTUMSOS1MAPT | |
| SCHEMBL29614460 | 0.80 | NOTUM (0.50) | CFTRNOTUMSOS1MAPTNPSR1 | |
| SCHEMBL21200958 | 0.80 | NOTUM (0.50) | CFTRNOTUMSOS1MAPTNPSR1 | |
| SCHEMBL22824685 | 0.79 | CFTR (0.49) | CFTRNOTUMSOS1MAPTTSHR | |
| SCHEMBL29366525 | 0.79 | CFTR (0.49) | CFTRNOTUMSOS1MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| EP-3743063-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | Nurix Therapeutics, Inc. (US) | 2020-12-02 | — | — | EP | disclosed |
| WO-2019148005-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | CBLB, CBL, CBLC | EPHX2 2500/4885CFTR 3832/4885NOTUM 3479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.